Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia

• Status: Completed
• Trial end date: 2013-08-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving combination chemotherapy together with rituximab may kill more cancer cells.

PURPOSE: This phase II trial is studying how well giving combination chemotherapy together with rituximab works in treating patients with newly diagnosed Burkitt's lymphoma or leukemia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Collaborator: National Cancer Institute (NCI)
• Treatments: Cortisol succinate; Cyclophosphamide; Cytarabine; Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate; Leucovorin; Levoleucovorin; Methotrexate; Prednisone; Rituximab; Vincristine

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed diagnosis of 1 of the following:

• Classic, sporadic Burkitt's lymphoma

• Burkitt's leukemia (FAB L3 acute lymphoblastic leukemia)

• Atypical Burkitt/Burkitt's-like lymphoma or leukemia, defined by the following criteria:

• Characteristic morphologic features

• High proliferative index AND Ki-67 ≥ 85%

• Any stage allowed

• Newly diagnosed or untreated disease

• Steroids allowed

PATIENT CHARACTERISTICS:

Age

• 30 and over

Performance status

• Not specified

Life expectancy

• Not specified

Renal

• No known irreversible renal dysfunction that would preclude treatment with high-dose cyclophosphamide

Cardiovascular

• No known significant cardiac dysfunction that would preclude treatment with high-dose cyclophosphamide

Other

• Not pregnant or nursing

• No known HIV positivity

• No other malignancy within the past 3 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• No prior chemotherapy for lymphoma

• A maximum of 2 prior doses of intrathecal chemotherapy are allowed

Endocrine therapy

• Not specified

Radiotherapy

• No prior radiation therapy for lymphoma

Surgery

• Prior complete or incomplete surgical resection of lymphoma allowed